[go: up one dir, main page]

PE20030292A1 - Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gabaa - Google Patents

Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gabaa

Info

Publication number
PE20030292A1
PE20030292A1 PE2002000626A PE2002000626A PE20030292A1 PE 20030292 A1 PE20030292 A1 PE 20030292A1 PE 2002000626 A PE2002000626 A PE 2002000626A PE 2002000626 A PE2002000626 A PE 2002000626A PE 20030292 A1 PE20030292 A1 PE 20030292A1
Authority
PE
Peru
Prior art keywords
heteroaryl
alkyl
compounds
gabaa
imidazol
Prior art date
Application number
PE2002000626A
Other languages
English (en)
Inventor
Alan Hutchinson
George Maynard
Linghong Xie
Scott Mitchell
Manuka Ghosh
Nian Liu
Kevin Currie
Guiying Li
Vinod Singh
Jun Yuan
Pamela Albaugh
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of PE20030292A1 publication Critical patent/PE20030292A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTOS DE HETEROARILO BICICLICOS FUSIONADOS SUBSTITUIDOS CON HETEROARILO DE FORMULA I DONDE Z1 ES N, CR1; Z2 ES N, CR2; Z3 ES N, CR3; Z4 ES N, CR4; Z5 ES N, C; Z6 ES N, C SIEMPRE QUE NO MAS DE DOS Z1-Z6 SEAN N; R1-R4 SON H, HALOGENO, HIDROXI, NITRO, CIANO, AMINO, ENTRE OTROS, ALQUILO, ALCOXI, CICLOALQUILO, ALQUENILO ENTRE OTROS; R5 ES H, HALOGENO, CIANO, HALOALQUILO O R5 REPRESENTA ALQUILO, CICLOALQUILO, ARILO, ARILALQUILO, HETEROARILO, ENTRE OTROS; Q ES -C(R6)(R7), -N(ALQUILO)-, O, CON LA CONDICION DE QUE Q NO SEA O CUANDO X2 ES N; R6 Y R7 ES H, F, ALQUILO; Y ES N, C, -CH-, -CH2-; W ES ARILO, HETEROARILO. SON COMPUESTOS PREFERIDOS 6-CLORO-2-[(2-FENIL-1H-IMIDAZOL-1-IL)METIL]-3-PROPILIMIDAZO[1,2-a]PIRIDINA, 6-CLORO-2-{[2-(3-FLUOROFENIL)-1H-IMIDAZOL-1-IL]METIL}IMIDAZO[1,2-a]PIRIDINA, 6-CLORO-2-{[2-(3-CLOROFENIL)-1H-IMIDAZOL-1-IL]METIL}IMIDAZO[1,2-a]PIRIDINA, ENTRE OTROS. SE REFIERE TAMBIEN A COMPUESTOS DE HETEROARILO BICICLICOS TAL COMO IMIDAZOPIRIDINAS, IMIDAZOPIRAZINAS, IMIDAZOPIRIDAZINAS , IMIDAZOPIRIMIDINAS E IMIDAZOTIAZOLES SUBSTITUIDOS CON HETEROARILO Y DE MANERA MAS ESPECIFICA CON LOS COMPUESTOS QUE SE ENLAZAN CON ELEVADA SELECTIVIDAD Y ELEVADA AFINIDAD CON LOS LUGARES DE BENZODIAZEPINA DE LOS RECEPTORES GABAA UTIL PARA EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL
PE2002000626A 2001-07-13 2002-07-12 Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gabaa PE20030292A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30553301P 2001-07-13 2001-07-13

Publications (1)

Publication Number Publication Date
PE20030292A1 true PE20030292A1 (es) 2003-04-03

Family

ID=23181185

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000626A PE20030292A1 (es) 2001-07-13 2002-07-12 Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gabaa

Country Status (16)

Country Link
US (2) US6936617B2 (es)
EP (1) EP1406906A1 (es)
JP (1) JP2005505518A (es)
KR (1) KR20040015356A (es)
CN (2) CN101220027A (es)
AR (1) AR036168A1 (es)
BR (1) BR0211124A (es)
CA (1) CA2453554A1 (es)
GT (1) GT200200148A (es)
IL (1) IL159811A0 (es)
MX (1) MXPA04000372A (es)
NZ (1) NZ530992A (es)
PA (1) PA8550401A1 (es)
PE (1) PE20030292A1 (es)
UY (1) UY27380A1 (es)
WO (1) WO2003006471A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003099284A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
JP4555082B2 (ja) 2002-08-08 2010-09-29 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよびそれの治療での使用
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
DE10247271A1 (de) * 2002-10-10 2004-08-26 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yle
ZA200600037B (en) * 2003-07-25 2007-04-25 Neurogen Corp Imidazo-pyrimidines and triazolo-pyrimidines: Benzodiazepine receptor ligands
PL1648899T3 (pl) 2003-07-25 2007-06-29 Neurogen Corp Imidazo-pirymidyny i triazolo-pirymidyny: ligandy benzodiazepinowego receptora
EP1880998A1 (en) * 2003-07-25 2008-01-23 Neurogen Corporation Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
AU2005212438A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
CA2555263A1 (en) * 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
WO2006052546A2 (en) * 2004-11-04 2006-05-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US7709468B2 (en) * 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
PT2495016T (pt) 2005-12-23 2019-12-16 Ariad Pharma Inc Compostos de heteroarilo bicíclicos
BRPI0710331A2 (pt) * 2006-05-08 2012-03-20 Ariad Pharmaceuticals, Inc Compostos heteroarila monocíclicos para tratamento de câncer e composição
CN103435595A (zh) * 2006-05-08 2013-12-11 阿里亚德医药股份有限公司 炔类杂芳基化合物
US20080249305A1 (en) * 2007-03-27 2008-10-09 Calderwood David J Novel imidazole based heterocycles
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
EP2072516A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
US8263630B2 (en) 2008-02-12 2012-09-11 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
US10206921B2 (en) 2009-06-03 2019-02-19 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (CNS) injury
EP2298296A1 (en) * 2009-08-25 2011-03-23 CNRS Centre National De La Recherche Scientifique Composition and method for treating cognitive impairments in down syndrome subjects
US20120220581A1 (en) 2009-10-30 2012-08-30 Janssen-Cilag, S.A. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US20130150351A1 (en) * 2010-06-03 2013-06-13 Stanley T. Carmichael Methods and compositions for treating a subject for central nervous system (cns) injury
KR101034040B1 (ko) * 2010-08-16 2011-05-16 정동영 백업트랙터
EP2723744B1 (en) 2011-06-27 2016-03-23 Janssen Pharmaceutica, N.V. 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
ES2607184T3 (es) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
CA3167093A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
RS59534B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
AU2015374118B2 (en) 2014-12-29 2020-07-23 The Trustees Of The University Of Pennsylvania Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
MX389824B (es) 2015-08-12 2025-03-20 Incyte Holdings Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
IL262488B (en) 2016-04-22 2022-08-01 Incyte Corp lsdi inhibitor formulations
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN111662270A (zh) * 2019-03-05 2020-09-15 中国医学科学院药物研究所 碘同位素标记苄苯醚衍生物、及其制法和药物组合物与用途
CN118515663A (zh) * 2023-04-24 2024-08-20 上海赛默罗生物科技有限公司 咪唑并吡啶或咪唑并吡嗪类化合物、其制备方法、药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001333A1 (en) * 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
AU5348396A (en) * 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
GB9805557D0 (en) 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
GB9805561D0 (en) 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
GB9805559D0 (en) 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6358949B1 (en) 1999-04-02 2002-03-19 Neurogen Corporation Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
AU2001236471A1 (en) 2000-01-18 2001-07-31 Neurogen Corporation Imidazopyridines and related azacyclic derivatives as selective modulators of bradykinin b2 receptors
WO2002002557A2 (en) * 2000-06-30 2002-01-10 Neurogen Corporation 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa

Also Published As

Publication number Publication date
CA2453554A1 (en) 2003-01-23
PA8550401A1 (es) 2004-02-07
CN100369912C (zh) 2008-02-20
MXPA04000372A (es) 2004-07-23
AR036168A1 (es) 2004-08-18
EP1406906A1 (en) 2004-04-14
GT200200148A (es) 2003-05-15
US20060014746A1 (en) 2006-01-19
US6936617B2 (en) 2005-08-30
CN101220027A (zh) 2008-07-16
US20030207885A1 (en) 2003-11-06
JP2005505518A (ja) 2005-02-24
KR20040015356A (ko) 2004-02-18
BR0211124A (pt) 2004-06-29
CN1553916A (zh) 2004-12-08
WO2003006471A1 (en) 2003-01-23
NZ530992A (en) 2005-06-24
UY27380A1 (es) 2003-02-28
IL159811A0 (en) 2004-06-20

Similar Documents

Publication Publication Date Title
PE20030292A1 (es) Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gabaa
PE20030129A1 (es) Imidazotriazinas
Couty et al. Synthesis of 3-(arylmethylene) isoindolin-1-ones from ynamides by Heck–Suzuki–Miyaura domino reactions. Application to the synthesis of lennoxamine
PE20040593A1 (es) DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA AMINO SUSTITUIDOS COMO INHIBIDORES DE TIROSINACINASAS DEL GRUPO SRC
PE20010629A1 (es) Derivados de triazolpiridinamina como ligandos de receptores de adenosina
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
PE20030845A1 (es) Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios
WO2001034603A3 (en) Bicyclic and tricyclic heteroaromatic compounds
PE20000467A1 (es) Derivado de indol util como inhibidor de serotonina
PE20011305A1 (es) Agentes diazabiciclicos activos en el snc
PE20030922A1 (es) Derivados de piridina y quinolina
PE91198A1 (es) DERIVADOS PIRIDO[3,4-d]PIRIMIDINA
PE20030155A1 (es) Azaindoles como inhibidores de quinasas
PE20050465A1 (es) Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
UY27179A1 (es) Novedosos derivados heterociclicos de los carbonilos y sus usos como ligandos del receptor d3 de la dopamina
UY24016A1 (es) Derivados triciclicos del pirazol
PE20020970A1 (es) Derivados de imidazo-pirimidina como ligandos para los receptores de gaba
ES2154470T3 (es) Derivados de tetrahidroisoquinolina y su uso farmaceutico.
Kundu et al. New application of pictet− spengler reaction leading to the synthesis of an unusual seven-membered heterocyclic ring system
Khaikate et al. Synthesis of Indolo-and Benzothieno [2, 3-b] quinolines by a Cascade Cyclization of o-Alkynylisocyanobenzene Derivatives
Walz et al. Synthesis of 8-methoxy-1-methyl-1 H-benzo [de][1, 6] naphthyridin-9-ol (isoaaptamine) and analogues
PE20040763A1 (es) Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6
ES2183866T3 (es) Derivados de beta-aril y beta-heteroaril-alfa-cianoacrilamidas sustituido como inhibidors de la tirosina quinasa.
Zhou et al. Explorations on the asymmetric total synthesis of isoschizogamine

Legal Events

Date Code Title Description
FA Abandonment or withdrawal